Health Invest Partners Ab Bei Gene, Ltd. Transaction History
Health Invest Partners Ab
- $221 Million
- Q2 2025
A detailed history of Health Invest Partners Ab transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Health Invest Partners Ab holds 24,386 shares of BGNE stock, worth $5.53 Million. This represents 2.5% of its overall portfolio holdings.
Number of Shares
24,386
Previous 25,141
3.0%
Holding current value
$5.53 Million
Previous $5.7 Million
3.0%
% of portfolio
2.5%
Previous 2.64%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
282Shares Held
35.8MCall Options Held
110KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.2% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...